Centric Compounding initiated a nationwide recall of three injectable drug lots over contamination concerns tied to an active pharmaceutical ingredient (API). The recall targets specific lots of Glutathione, a peptide injectable drug dispensed by the Houston-based pharmacy. Regulatory-watch implications are straightforward for biotech and clinical operations: injectable contamination events can trigger heightened scrutiny of supply chains, compounding processes, and lot-level release documentation. Even when the recalled products are compounded rather than sponsor-manufactured biologics, downstream providers often need to verify inventory and administration records. In a separate operational shift, Sionna Therapeutics laid off 46% of staff after a cystic fibrosis trial failure, reflecting how development and corporate resource plans respond to clinical readouts. Together, the cluster points to two pressure points in execution: manufacturing assurance for injectable products and financial runway management when trials do not deliver.